HIMS SECURITIES NEWS: Did Hims & Hers Health, Inc. (NYSE:HIMS) Commit Securities Fraud? Contact BFA Law by August 25 Class Action Deadline
If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.
Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sookdeo v. Hims & Hers Health, Inc., et al. , No. 25-cv-05315. A subsequent complaint alleging substantially similar claims was also filed and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al. , No. 25-cv-05321.
Why was Hims & Hers Sued for Securities Fraud?
Hims & Hers operates a telehealth platform that provides consumers with access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a 'long-term collaboration' starting with the immediate sale of Novo Nordisk's popular weight loss drug Wegovy on the Hims & Hers platform. The active ingredient in Wegovy is semaglutide.
As alleged, Hims & Hers touted and misrepresented to investors the nature of its partnership with Novo Nordisk, including asserting that under the terms of the agreement His & Hers could offer both Wegovy and compounded semaglutide to its customers. Hims & Hers also allegedly represented to investors that its sale of compounded semaglutide complied with FDA regulations.
The Stock Declines as the Truth is Revealed
On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk' and alleged that Hims & Hers 'failed to adhere to the law which prohibits mass sales of compounded drugs.' On this news, the price of Hims & Hers stock fell $22.24 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.98 per share on June 23, 2025.
Click here for more information: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action.
What Can You Do?
If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action
Or contact:Ross Shikowitz
[email protected]
212-789-3619
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
21 minutes ago
- Business Upturn
Simulations Plus (SLP) Faces Investor Scrutiny After Asset Impairments and Grant Thornton Contests Company Statements About Dismissal — Hagens Berman
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) — Investors in Simulations Plus, Inc. (NASDAQ: SLP) saw the price of their shares decline about 25% on July 15, 2025 after the company reported its Q3 2025 $67.3 million net loss that included a $77.2 million impairment charge and the company's firing of its independent auditor Grant Thornton, whom it hired on April 15, 2025. Simulations Plus's revelation has prompted national shareholders rights firm Hagens Berman to open an investigation into whether the company may have misled investors about its asset valuations and the reasons why it abruptly dismissed Grant Thornton and urges Simulations Plus investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: Contact the Firm Now: [email protected] 844-916-0895 Simulations Plus, Inc. (SLP) Investigation: The investigation is focused on the propriety of Simulations Plus' statements concerning its asset values and the basis of its dismissal of independent auditor Grant Thornton. The inquiry stems from a series of events earlier this month. On July 14, Simulations Plus announced a $77.2 million charge, stating it adjusted the book value of its assets to align with current market values. The following day, in a separate disclosure, the company revealed it had terminated its engagement with Grant Thornton on July 9. Simulations Plus had initially hired Grant Thornton on April 15, 2025. Simulations Plus explained the auditor change by stating that during Grant Thornton's brief tenure, the company reviewed matters concerning segment reporting and reporting unit determinations that could not be finalized for its May 31, 2025, quarterly report. The company also evaluated internal controls over financial reporting related to Sarbanes-Oxley Act Section 404(a) compliance, concluding these could not be finalized in time for the same report. Simulations Plus added that there were no 'reportable events' as defined by SEC regulations. Grant Thornton, however, disputed Simulations Plus's account in a letter to the Securities and Exchange Commission. The auditing firm stated its disagreement with the company's disclosure. Grant Thornton further indicated that during its review of Simulations Plus's consolidated financial statements for the quarter ended May 31, 2025, it had identified and communicated specific concerns to management and the Audit Committee related to segment reporting, reporting unit determinations, and internal controls over financial reporting. 'We're investigating whether Simulations Plus may have misled investors about the value of its assets and why it abruptly fired Grant Thornton and rehired its old auditor,' said Reed Kathrein, the Hagens Berman partner leading the investigation. If you invested in Simulations Plus and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the Simulations Plus investigation, read more » Whistleblowers: Persons with non-public information regarding Simulations Plus should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw. Contact: Reed Kathrein, 844-916-0895 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
21 minutes ago
- Business Upturn
Frequency Electronics Announces 2025 Quantum Sensing Summit in New York City
MITCHEL FIELD, N.Y., Aug. 01, 2025 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. ('FEI' or the 'Company') (NASDAQ-FEIM), a leading provider of precision timing and frequency control products, today announced it will host the 2025 Quantum Sensing Summit on October 29–30, 2025, in New York City. The event will bring together leaders from government, industry, and research to accelerate the transition of quantum sensing technologies from the lab to mission-ready deployment. Building on the success of the inaugural 2024 summit, this year's two-day program will feature keynotes, panels, and technical sessions highlighting enabling technologies such as Rydberg and NV-diamond sensors, photonic integrated circuits (PICs), frequency combs, and ultra-low-noise oscillators. 'Quantum sensing is at the heart of the next technological revolution,' said Dr. Tom McClelland, CEO of Frequency Electronics. 'This summit is designed to forge the partnerships and strategies that turn today's breakthroughs into tomorrow's deployable solutions.' The summit is expected to attract 100–150 participants, including key government decision-makers, program managers, and industry innovators, providing a unique forum for collaboration and policy influence in the emerging quantum technology landscape. About Frequency Electronics Frequency Electronics, Inc. (FEI) is a world leader in the design, development and manufacture of high precision timing, frequency generation and RF control products for space and terrestrial applications. FEI's products are used in satellite payloads and in other commercial, government and military systems including C4ISR and electronic warfare, missiles, UAVs, aircraft, GPS, secure communications, energy exploration and wireline and wireless networks. FEI-Zyfer provides GPS and secure timing capabilities for critical military and commercial applications; FEI-Elcom Tech provides Electronic Warfare ('EW') sub-systems and state-of-the-art RF and microwave products. FEI has received over 100 awards of excellence for achievements in providing high performance electronic assemblies for over 150 space and DOD programs. The Company invests significant resources in research and development to expand its capabilities and markets. FEI's Mission Statement: 'Our mission is to transform discoveries and demonstrations made in research laboratories into practical, real-world products. We are proud of a legacy which has delivered precision time and frequency generation products, for space and other world-changing applications that are unavailable from any other source. We aim to continue that legacy while adapting our products and expertise to the needs of the future. With a relentless emphasis on excellence in everything we do, we aim, in these ways, to create value for our customers, employees, and stockholders.' Forward-Looking Statements The statements in this press release regarding future earnings and operations and other statements relating to the future constitute 'forward-looking' statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, our inability to integrate operations and personnel, actions by significant customers or competitors, general domestic and international economic conditions, reliance on key customers, continued acceptance of the Company's products in the marketplace, competitive factors, new products and technological changes, product prices and raw material costs, dependence upon third-party vendors, other supply chain related issues, increasing costs for materials, operating related expenses, competitive developments, changes in manufacturing and transportation costs, the availability of capital, the outcome of any litigation and arbitration proceedings, and failure to maintain an effective system of internal controls over financial reporting. The factors listed above are not exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the Securities and Exchange Commission. The Company's Annual Report on Form 10-K for the fiscal year ended April 30, 2024, filed on August 2, 2024 with the Securities and Exchange Commission includes additional factors that could materially and adversely impact the Company's business, financial condition and results of operations, as such factors are updated from time to time in our periodic filings with the Securities and Exchange Commission, which are accessible on the Securities and Exchange Commission's website at Moreover, the Company operates in a very competitive and rapidly changing environment. New factors emerge from time to time and it is not possible for management to predict the impact of all these factors on the Company's business, financial condition or results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not rely on forward-looking statements as a prediction of actual results. Any or all of the forward-looking statements contained in this press release and any other public statement made by the Company or its management may turn out to be incorrect. The Company expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact information: Dr. Thomas McClelland, President and Chief Executive Officer; Steven Bernstein, Chief Financial Officer; TELEPHONE: (516) 794-4500 ext.5000 WEBSITE: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
21 minutes ago
- Business Upturn
Centene Corporation (CNC) Faces Shareholder Ire Amidst Plummeting Stock and Lawsuit Over 'Inflated Guidance'
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) — Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results. The company, a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks to represent investors who purchased or acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934. National shareholders rights firm Hagens Berman continues to investigate the securities law claims and urges Centene investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Dec. 12, 2024 – June 30, 2025 Lead Plaintiff Deadline: Sept. 8, 2025 Visit: Contact the Firm Now: [email protected] 844-916-0895 Centene Q2 2025 Financial Results On July 25, 2025, Centene reported a GAAP diluted loss per share of -$0.51 'driven primarily by a reduction in the Company's net 2025 Marketplace risk adjustment revenue transfer estimate.' The Centene Securities Class Action Centene Corporation and its top executives are facing a class-action lawsuit accusing them of portraying an overly optimistic view of the company's financial health and future prospects, misleading investors about its enrollment and market conditions. According to the complaint, during the alleged Class Period, Centene's leadership gave the impression that it had solid, reliable information about projected revenue growth while touting strong enrollment rates and low morbidity levels among its members. For months, Centene's public statements painted a picture of expanding market share and a robust business, particularly focused on serving underinsured and uninsured populations. Yet, the lawsuit alleges that these upbeat reports were disconnected from reality. A preliminary analysis covering more than two-thirds of Centene's Marketplace share reportedly showed lower-than-expected enrollment alongside higher aggregate morbidity rates. This disparity between official statements and internal data forms the core grievance of shareholders. The situation reached a critical point on July 1, 2025, when Centene abruptly withdrew its 2025 financial guidance. The company cited a thorough review of Marketplace data from independent actuarial firm Wakely, revealing that market growth across Centene's 22 Health Insurance Marketplace states was 'lower than expected,' with morbidity levels significantly exceeding and 'materially inconsistent with' the company's earlier assumptions for risk adjustment revenue transfer used in its 2025 guidance. This unexpected revision led to the elimination of Centene's guidance, sending its stock tumbling more than 40 percent and wiping out billions in shareholder value overnight. The lawsuit contends that investors were misled by a narrative of sustained growth and healthy enrollment that, in truth, did not reflect the company's operational realities. 'The allegations, if proven true, suggest a pattern of where Centene's public optimism didn't align with the internal metrics, ultimately leaving investors holding the bag,' stated Reed Kathrein, a partner at Hagens Berman. If you invested in Centene and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the Centene investigation, read more » Whistleblowers: Persons with non-public information regarding Centene should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw. Contact: Reed Kathrein, 844-916-0895 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
